REMARKS

Claims 1-22 are pending in the present application. Claims 1-10 and 12-20 are withdrawn from consideration. Claims 11, 21 and 22 are rejected. Applicants herein amend claim 11 to still further distinguish over the prior art by adding the recitation "colon" to describe the particular tumor cells. The change is made purely in the interest of advancing prosecution and securing prompt issuance of a patent. No issue of new matter arises as express support may be found for instance, in the Abstract, and paragraphs [0001] and [0003].

Applicants are pleased that the last Amendment and Response filed on October 3, 2006 was completely successful in overcoming all the rejections made to that point. However, the Examiner now rejects all of the pending claims 11, 21 and 22 as anticipated by Au-Young *et al.*, WO 01/07612.

According to the Examiner, Au-Young *et al.* teach a polypeptide, SEQ ID NO:21 that is 100% identical to SEQ ID NO:1 of the instant application. Allegedly, Au-Young *et al.* teach producing antibodies that specifically bind their sequence, administering a therapeutically effective amount of the antibodies to treat cancer, that the antibodies may be polyclonal, monoclonal, chimeric, single chain, an Fab fragment or a fragment from an Fab expression library, and that the antibody may be conjugated to a detectable label or therapeutic moiety.

Applicants submit that Au Young *et al.* disclose 22 nucleic acid sequences, encoded polypeptides and antibodies thereto for diagnosing, treating and preventing neurological disorders, immunological disorders, including autoimmune and inflammatory disorders, and cell proliferative disorders, including cancer. Further, Au-Young *et al.* indicate that these sequences are supposedly useful for treating a long list of disorders. (*See,* pages 36 and 37). Au-Young *et al.* do not teach or suggest that a RAIG1 polypeptide (SEQ ID NO: 21) is expressed, let alone upregulated in colon cancer cells. Rather, Au-Young *et al.* merely indicate the diseases,

disorders and conditions associated with the nucleic acid sequence of SEQ ID NO: 43 (encoding the amino acid sequence of SEQ ID NO:21). (*See,* Table 3). Such disorders and conditions include, for instance, cancer, inflammation and cell proliferation. Hence, Au-Young *et al.* do not teach or suggest the RAIG1 polypeptide is upregulated in colon cancer cells.

CONCLUSION

It is believed that all of the claims are patentable and early notification as such is earnestly solicited. If any issues may be resolved by way of telephone, the Examiner is invited to call the undersigned at the telephone number indicated below.

Respectfully submitted,



J. David Smith
Attorney for Applicants
Registration No. 39,839

KLAUBER & JACKSON
411 Hackensack Ave., 4th Floor
Hackensack, NJ 07601
(201) 487-5800